期刊
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
卷 68, 期 11, 页码 2435-2444出版社
OXFORD UNIV PRESS
DOI: 10.1093/jac/dkt221
关键词
5-FC; cryptococcal meningitis; cryptococcal meningitis treatment guidelines; access to essential antifungals for cryptococcal meningitis; 5-FC safety; combination antifungal therapy; opportunistic infection
资金
- MRC (UK)
- ANRS (France)
- Wellcome Trust
- MRC [G1100684] Funding Source: UKRI
- Medical Research Council [G1100684] Funding Source: researchfish
Current, widely accepted guidelines for the management of HIV-associated cryptococcal meningoencephalitis (CM) recommend amphotericin B combined with flucytosine (5-FC) for >= 2 weeks as the initial induction treatment of choice. However, access to flucytosine in Africa and Asia, where disease burden is greatest, is inadequate at present. While research into identifying effective and well-tolerated antifungal combinations that do not contain flucytosine continues, an ever-increasing body of evidence from in vitro, in vivo and clinical studies points to the benefits of flucytosine in the treatment of CM in both intravenous combinations with amphotericin B and oral combinations with high-dose fluconazole. This article provides an up-to-date review of this evidence, and the current issues and challenges regarding increasing access to this key component of combination antifungal therapy for cryptococcosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据